Biogen has agreed to buy a phase 2b trial-ready schizophrenia treatment from Pfizer for up to $590m. The price includes an upfront payment of $75m with up to $515m in additional development and commercialisation milestone payments, as well as tiered royalties in the low to mid-teen percentages. Biogen said the drug, PF-04958242, has previously demonstrated an acceptable safety profile and treatment effect trends across multiple domains of cognition in phase 1b clinical studies. The company plans ...Den vollständigen Artikel lesen ...